FDA Advisory Committee Discusses Key Peptides for 503A Bulk List Inclusion

What this means for your practice

For healthcare businesses, including telehealth brands, medspas, and other practices that prescribe or administer compounded medications, the outcome of the FDA's Pharmacy Compounding Advisory Committee meetings regarding bulk drug substances for the 503A list carries significant weight. Peptides like BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon are widely utilized in various therapeutic areas. Their status on the 503A list directly impacts compounding pharmacies' ability to legally prepare these substances for patient-specific prescriptions.

Practices relying on compounded peptide therapies must closely monitor the FDA's final recommendations following this advisory committee meeting. If a peptide is not included on the 503A list, compounding pharmacies may face severe restrictions on their ability to source and compound that substance. This could disrupt current treatment protocols, require practices to seek alternative therapies, or necessitate adjustments to their service offerings. Ensuring compliance with compounding regulations is paramount, and understanding the lawful status of bulk drug substances is a foundational aspect of this compliance. Businesses should consult with their compounding pharmacies and legal counsel to assess the impact of these decisions on their operations and patient care strategies.

Silver Spring, MD – The U.S. Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee convened on July 23-24, 2026, to conduct a comprehensive review of several peptide-related bulk drug substances. The committee's central task was to consider adding these substances to the Section 503A bulk drug substances list, a determination that holds significant implications for pharmacies engaged in compounding and the healthcare clinics that rely on these specialized preparations.

Understanding the Section 503A Bulk Drug Substances List

Section 503A of the Federal Food, Drug, and Cosmetic Act outlines specific conditions under which human drug products compounded by a licensed pharmacist or physician are exempt from certain FDA requirements, such as new drug application approval and current good manufacturing practice (cGMP) regulations. A critical aspect of this exemption for traditional compounding pharmacies (often referred to as 503A pharmacies) is the requirement that, if a drug product is compounded from bulk drug substances, those substances must: 1. Comply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph and the USP chapter on pharmacy compounding, 2. Be components of an FDA-approved drug product, or 3. Appear on a list of bulk drug substances for which there is a clinical need, developed by the FDA in consultation with the Pharmacy Compounding Advisory Committee (the 503A bulk drug substances list).

The committee's deliberations are thus vital, as inclusion on this list provides a pathway for compounding pharmacies to legally utilize these substances for patient-specific prescriptions when no suitable FDA-approved drug product is available.

Peptides Under Scrutiny

The advisory committee dedicated its two-day meeting to examining seven distinct categories of peptide-related bulk drug substances. The discussions involved detailed presentations, including those from nominators advocating for the inclusion of these substances on the 503A list.

Substances Reviewed on July 23, 2026: * BPC-157-related bulk drug substances (BPC-157 (free base)/ BPC-157 acetate): * Uses Evaluated: Ulcerative colitis (UC) * KPV-related bulk drug substances (KPV (free base)/ KPV acetate): * Uses Evaluated: Wound healing and inflammatory conditions * TB-500-related bulk drug substances (TB-500 (free base)/ TB-500 acetate): * Uses Evaluated: Wound healing * MOTs-C-related bulk drug substances (MOTs-C (free base)/ MOTs-C acetate): * Uses Evaluated: Obesity and osteoporosis

Substances Reviewed on July 24, 2026: * Emideltide (also referred to as delta sleeping inducing peptide (DSIP))-related bulk drug substances (Emideltide (free base)/ Emideltide acetate): * Uses Evaluated: Opioid withdrawal, chronic insomnia, and narcolepsy * Semax-related bulk drug substances (Semax (free base)/ Semax acetate): * Uses Evaluated: Cerebral ischemia, migraine, and trigeminal neuralgia * Epitalon-related bulk drug substances (Epitalon (free base)/ Epitalon acetate): * Uses Evaluated: Insomnia

The Role of the Advisory Committee

FDA advisory committees serve a crucial function by providing independent expert advice to the agency on various scientific topics and specific products. While these committees offer non-binding recommendations, the FDA generally gives considerable weight to their input when making final regulatory decisions. This process ensures that the agency's decisions are informed by a broad range of scientific expertise and public perspectives.

Public Participation and Next Steps

The meeting included opportunities for public comment, allowing interested parties to present data, information, or views either orally or in writing. The FDA established a public docket (FDA-2025-N-6895) for written comments, which closed on July 22, 2026.

Following the advisory committee's recommendations, the FDA will review all submitted information and make a final determination regarding the inclusion of these peptides on the 503A bulk drug substances list. Healthcare providers and compounding pharmacies are encouraged to monitor FDA announcements for these forthcoming decisions, as they will directly impact the availability and legal status of these compounded peptide therapies.

Key Facts

| Detail | Value | |---|---| | Committee | Pharmacy Compounding Advisory Committee | | Meeting Dates | July 23-24, 2026 | | Location | FDA White Oak Campus, Silver Spring, MD (and virtual attendance option) | | Substances Under Review | BPC-157-related, KPV-related, TB-500-related, MOTs-C-related, Emideltide-related, Semax-related, and Epitalon-related bulk drug substances | | Purpose | Consider adding substances to the Section 503A bulk drug substances list | | Public Comment Docket | FDA-2025-N-6895 (Closed July 22, 2026) |

Frequently Asked Questions

What was the purpose of the FDA Pharmacy Compounding Advisory Committee meeting?

The committee met to discuss and consider adding seven specific peptide-related bulk drug substances to the Section 503A bulk drug substances list.

What does being on the Section 503A bulk drug substances list mean for a compound?

Inclusion on this list allows traditional compounding pharmacies (503A pharmacies) to legally use these bulk substances to compound patient-specific prescriptions under certain exemptions from FDA requirements.

Which specific peptides were discussed at the meeting?

The peptides discussed were BPC-157-related, KPV-related, TB-500-related, MOTs-C-related, Emideltide-related (also DSIP), Semax-related, and Epitalon-related bulk drug substances.

Does the advisory committee's recommendation immediately make a substance eligible for compounding?

No, advisory committees provide independent expert advice and make non-binding recommendations to the FDA. The FDA generally follows these recommendations but is not legally bound to do so; a final agency decision is required.

How can the public stay informed about the FDA's decision on these peptides?

The FDA will make background material and a live webcast of the meeting available on its advisory committee calendar page. Interested parties should monitor FDA announcements for the agency's final determinations.

Source: fda.gov — FDA Advisory Committee Discusses Peptides for 503A Bulk List